Shows
WolverHeme Happy HourAn Exercise in Uncertainty with Jonathan GluckAnthony and Bernie are joined by special guest Jonathan Gluck, award-winning journalist and author of "An Exercise in Uncertainty: A Memoir of Illness and Hope" for a powerful conversation about living through uncertainty. Drawing on his decades-long journey with multiple myeloma, Jon reflects on the emotional, clinical, and existential uncertainties that shape living with cancer. The discussion moves beyond the patient experience to explore how uncertainty permeates everyday life, as well as oncology practice, including waiting for new therapies to become available, navigating logistical (and insurance) barriers, and interpreting evolving clinical trial data where...
2026-02-1046 minWolverHeme Happy HourASH Leukemia Review: the more we learn, the less we know!In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed:PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047FLT3i studies (and MRD): https://meetings-api...
2025-12-171h 23WolverHeme Happy HourRIP 7+3 (1973-2025)? Why PARADIGM Doesn't Deliver the EulogyAnthony and Bernie discuss the PARADIGM study that was presented at the plenary session of ASH 2025 and whether results should change our practice. https://meetings-api.hematology.org/api/abstract/vmpreview/296881
2025-12-0941 minWolverHeme Happy HourMajesTEC-3 and ASH 2025: Let's get "TEC"nicalIn this study, Bernie and Anthony are joined by the majestic myeloma man Manni Mohyuddin to discuss key ASH abstracts in myeloma, including the results of the MajesTEC-3 study!
2025-11-251h 09WolverHeme Happy HourEpisode 40: Coffee and Community HematologyIn this episode, Anthony and Bernie discuss the important role of community hematology. We discuss innovative research models, partnerships between community and academic practices, and ways to improve care for hematology patients who live near and far!
2025-10-2451 minWolverHeme Happy HourChill For 5: The Febrile Neutropenia Survival GuideIn this episode, Bernie and Anthony review the optimal management of febrile neutropenia! We talk about some historical data, optimal patient workup, proper selection of antibiotics, and a discussion of newer data regarding early antibiotic de-escalation in FN.
2025-10-0949 minWolverHeme Happy HourEpisode 38: Prophy and Pints!We're back after a summer break! In this episode, Anthony and Bernie review the optimal approach to antimicrobial prophylaxis in hematology patients. How do you best choose prophylaxis for your patients? Where are we using data and where are we just making things up? Does everyone need antifungal, antibacterial, antiviral, and anti-PJP prophylaxis? We will demystify prophylaxis guidelines for you!
2025-09-1049 minWolverHeme Happy HourEpisode 37: Spilling Drinks over Cytarabine DosingIn this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice? Hunault, et al. NEJM. 2025.https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326
2025-07-1158 minWolverHeme Happy HourEpisode 36: ODAC - Our Decisions Are ConfusingIn this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!
2025-05-2843 minWolverHeme Happy HourCSO Encore Video Presentation - SWOG1826 & STARGLO Trials Critically ExaminedThis is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/
2025-05-051h 10WolverHeme Happy HourDex and the Cytokine City: Managing CRS with BispecificsIn this episode, Bernie and Anthony are joined by 3 hematology pharmacists - James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; and Justine Preedit, PharmD, BCOP - to discuss the optimal management of CRS in patients receiving bispecific antibodies!Inspired by this recent paper:https://www.nature.com/articles/s41408-025-01222-y
2025-04-0759 minWolverHeme Happy HourLFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AMLIn this episode, Bernie and Anthony are joined by Dr. Charlie Foucar and Dr. Anand Patel to review the interesting and controversy-filled saga of gemtuzumab in AML? Should we be using this agent in AML? Tune in to find out!
2025-03-111h 04WolverHeme Happy HourEpisode 32: Navigating a BlinatumoMAD WorldIn this episode, Anthony and Bernie are joined by two special guests to discuss recent updates to the use of blinatumomab in both adult and pediatric acute lymphoblastic leukemia (ALL), including the results of the AALL1731 trial and the full publication of ECOG1910.
Julia Brown, PharmD, a Pediatric Hematology/Oncology Clinical Pharmacist and Lydia Benitez, an Adult Outpatient Leukemia Clinical Pharmacist bring their unique perspectives and expertise on the proper incorporation of blinatumomab into ALL care, as well as some of the major practical nuances that will be helpful to providers across the globe!
Finally...
2025-01-211h 06WolverHeme Happy HourThe Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple MyelomaAQUILA is a constellation shaped like an eagle, and also a hotly debated myeloma trial of daratumumab in smoldering multiple myeloma. In this episode, Bernie and Anthony are joined by myeloma expert Manni Mohyuddin to discuss the study's findings and whether or not they should change practice! Grab a drink and listen in for an exciting discussion.
Note: L'aquila is Italian for eagle!
AQUILA: Dimopoulos MA, et al. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Epub ahead of print. PMID: 39652675.
2025-01-1549 minWolverHeme Happy HourPour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma UpdatesIn this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen!
Some selected abstracts:
EA4151:
https://ash.confex.com/ash/2024/webprogram/Paper212973.html
Triangle Updates:
https://ash.confex.com/ash/2024/webprogram/Paper200735.html ,
https://ash.confex.com/ash/2024/webprogram/Paper201441.html
EA4181:
https://ash.confex.com/ash/2024/webprogram/Paper194641.html
ENRICH:
https://ash.confex.com/ash/2024/webprogram/Paper199710.html
inMIND:
https://ash.confex.com/ash/2024/webprogram/Paper212970.html
POLARIX Long-Term...
2024-12-241h 03WolverHeme Happy HourA Bunch of ASHholes Discuss Myeloma AbstractsIn this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!
2024-11-1656 minWolverHeme Happy HourCast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin LymphomaIn this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
2024-11-0848 minWolverHeme Happy HourEpisode 27: Mantle Cell Masterclass with Tycel PhillipsIn this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL.
TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/
Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/
2024-10-101h 01WolverHeme Happy HourHouston, we don't have a problem... with APOLLOIn this episode, Anthony and Bernie discuss the recently reported APOLLO trial in high-risk APL and debate whether this should represent the new standard of care in this population. We also review key practical considerations for the treatment of APL patients, including side effect management and treatment of APL in unique clinical scenarios.
APOLLO: https://library.ehaweb.org/eha/2024/eha2024-congress/422206/uwe.platzbecker.first.results.of.the.apollo.trial.a.randomized.phase.iii.study.html
2024-08-2858 minWolverHeme Happy HourFrom Ancient Remedies to Modern Miracles: The Evolution of APL TreatmentIn this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024!
How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today?
And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out!
2024-06-1358 minWolverHeme Happy HourEpisode 24: Myeloma Madness with the Myeloma ManIn this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.
2024-04-1758 minWolverHeme Happy HourAnthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussionIn this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!
Abstracts discussed:
https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R...
2024-01-2557 minWolverHeme Happy HourLymphOMG: Pouring Over Lymphoma Abstracts from ASHOMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!
Abstracts Discussed!
SYMPATICO (Ibrutinib + Ven in R/R MCL):
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Nivo-AVD in elderly Hodgkin Lymphoma:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL:
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
CAR-T in CNS Lymphoma:
https://ash.confex.com/ash/2023/webprogram/Paper174883...
2023-12-291h 12WolverHeme Happy HourAMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven AlchemyIn this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial!
Abstracts:
FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html
Revumenib Late Breaking Abstract:
https://ash.confex.com/ash/2023/webprogram/Paper192042.html
JNJ617 Menin Inhibitor Data:
https://ash.confex.com/ash/2023/webprogram/Paper172422.html
SAVE Trial (Revumenib + PO Dec/ven):
https://ash.confex.com/ash/2023/webprogram/Paper182337.html
Dec/Ven vs. 3+7 Randomized Phase II:
https://ash.confex.com/ash/2023/webprogram/Paper181347.html
NCRI AML18 RCT:
https://ash.confex.com/ash/2023/webprogram/Paper185956.html
...
2023-12-1941 minWolverHeme Happy HourASH Pregaming - Myeloma Madness with Manni and Papa HemeIn this episode, Anthony and Bernie are joined by two very special guests - Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin - to discuss the most interesting myeloma abstracts at the upcoming 2023 ASH meeting! Will any of these change practice? Listen to find out!
Abstracts Discussed:
https://ash.confex.com/ash/2023/webprogram/Paper188547.html
https://ash.confex.com/ash/2023/webprogram/Paper181765.html
https://ash.confex.com/ash/2023/webprogram/Paper177954.html
https://ash.confex.com/ash/2023/webprogram/Paper191911.html
https://ash.confex.com/ash/2023/webprogram/Paper179866.html
https://ash...
2023-12-0152 minWolverHeme Happy HourAML Maintenance Part 2: a metaMORPHOsis?In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice!
Sorafenib observational study: https://pubmed.ncbi.nlm.nih.gov/30809038/
SORMAIN (sorafenib): https://pubmed.ncbi.nlm.nih.gov/32673171/
Chinese Sorafenib Phase III: https://pubmed.ncbi.nlm.nih.gov/32791048/
RADIUS (midostaurin): https://pubmed.ncbi.nlm.nih.gov/33288862/
AMLSG 16-10 (midostaurin): https://pubmed.ncbi.nlm.nih.gov/30563875/
MORPHO (EHA abstract): https://library.ehaweb.org/eha/2023/eha2023-congress/391322/faculty.presenters.bmt-ctn.1506.28...
2023-11-0854 minWolverHeme Happy HourAML Maintenance Part 1: Set Your QUAZARs to StunIn the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR study.
Key References:
QUAZAR AML-001: https://pubmed.ncbi.nlm.nih.gov/33369355/
QUAZAR Letter to the Editor: https://pubmed.ncbi.nlm.nih.gov/33789022/
ASH Abstract Data on impact of # of Consolidation Cycles: https://ash.confex.com/ash/2020/webprogram/Paper138498.html
Hovon 97 (Azacitidine SQ maintenance): https://pubmed.ncbi.nlm.nih.gov/30630862/
Mayer, et al. NEJM. 1994...
2023-10-2551 minWolverHeme Happy HourEpisode 17: The Hemophilia Eras TourIn this episode, we are joined by classical hematology experts, Madeleine Ochs, PharmD, BCOP and Justin Arnall, PharmD, BCOP, to teach us hemophilia 101!
In this T-Swift themed, episode, we discuss the history of hemophilia treatment (through the "eras") and how new agents may change the management of hemophilia patients.
2023-08-231h 39WolverHeme Happy HourCommon Sense Oncology: Outcomes That MatterIn this episode, Anthony and Bernie chat with Chris Booth, MD, and Aaron "Papa Heme" Goodman, MD, to talk about the Common Sense Oncology movement!
Join the Common Sense Oncology movement at this link (it's free!): https://commonsenseoncology.org/
Lancet Oncol paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00319-4/fulltext
2023-08-0137 minWolverHeme Happy HourAll too well: the reality of leukemia treatmentIn this episode, Anthony, Bernie, and Lydia are joined by a former patient, Madeline B, to talk about her ALL treatment journey. Drawing inspiration from Taylor Swift's upcoming concert and heartfelt ballad ("All Too Well"), this episode tackles some of the unique challenges, emotions, and considerations that come with helping adolescents and young adults (AYA) with treatment for acute leukemia. This is a must-listen for anyone taking care of AYA patients!
2023-06-0849 minWolverHeme Happy HourEpisode 14: A Quantum Leap in AML Treatment? Dissecting Quizartinib Data with Dr. Dale BixbyIn this episode, Anthony and Bernie are joined once again by special guest and hematology expert, Dr. Dale Bixby, to discuss the recent publication of the QUANTUM-First study of quizartinib in newly diagnosed AML. Should this study change practice in FLT3-ITD+ AML? Have we made a "Quantum Leap" in the treatment of these patients? Listen for a fun-filled discussion of the data!
Notable References:
QUANTUM-First Study: https://pubmed.ncbi.nlm.nih.gov/37116523/
WolverHeme Episode 8 (Pulling the Goalie on FLT3 Inhibitor Use in AML): https://podcasters.spotify.com/pod/show/wolverheme/episodes/Episode-8...
2023-05-091h 10WolverHeme Happy HourEpisode 13: You get blinatumomab! You get blinatumomab!Blinatumomab - it's Oprah's new favorite drug!
On this episode, Anthony and Bernie are joined by special guests Dr. Lydia Benitez and Dr. Patrick Burke to discuss the ECOG1910 trial of blinatumomab in adult ALL. Is this trial practice changing? Listen and find out!
ECOG1910 Late-Breaking Abstract: https://ash.confex.com/ash/2022/webprogram/Paper171751.html
2023-02-241h 08WolverHeme Happy HourEpisode 12: Tinder for T Cells - Bispecifics in DLBCLIn this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain.
Relevant Articles:
Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/
Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/
Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/
Mosunetuzumab...
2023-02-0858 minWolverHeme Happy HourEpisode 11: "Olu the Drunk Snowman" - IDH inhibitors in R/R AML with Dr. Jill LykonIn this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib?
Olutasidenib Phase I - Watts, et al. Lancet. 2023: https://pubmed.ncbi.nlm.nih.gov/36370742/
Olutasidenib Phase II ASH Abstract: https://ash.confex.com/ash/2022/webprogram/Paper167330.html
Ivosidenib Phase I escalation/expansion - Dinardo, et al. NEJM. 2018: https://p...
2023-01-2152 minWolverHeme Happy HourEpisode 10: ASH Recap Part 2 - Papa Heme + WolverHemeIn this episode, we are joined by the legendary hematologist and rock star - Dr. Aaron Goodman - aka "Papa Heme"! We discuss which ASH abstracts might be practice changing and which simply don't make the cut. Stay tuned for an entertaining and very educational episode!
2022-12-211h 13
PTCE Pharmacy Connect | Pharmacy TimesAdvances in the Treatment of Immune Thrombocytopenia: Strategies for Optimizing Clinical and Patient Outcomes | PTCE Pharmacy ConnectEducational Objectives
Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP)
Recall the efficacy and safety of emerging agents for the treatment of ITP
Moderator:
Anthony J. Perissinotti, PharmD, BCOP
To claim CE credit for this activity, please visit the link below:
https://www.pharmacytimes.org/courses/advances-in-the-treatment-of-immune-thrombocytopenia-strategies-for-optimizing-clinical-and-patient-outcomes
Hematology Clinical Pharmacist Specialist
Clinical Team Leader Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan – Michigan Medicine
Ann Arbor, Michigan
Fa...
2022-12-1949 min
PTCE Pharmacy Connect | Pharmacy TimesAdvances in the Treatment of Immune Thrombocytopenia: Strategies for Optimizing Clinical and Patient Outcomes | PTCE Pharmacy ConnectEducational Objectives
Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP)
Recall the efficacy and safety of emerging agents for the treatment of ITP
Moderator:
Anthony J. Perissinotti, PharmD, BCOP
To claim CE credit for this activity, please visit the link below:
https://www.pharmacytimes.org/courses/advances-in-the-treatment-of-immune-thrombocytopenia-strategies-for-optimizing-clinical-and-patient-outcomes
Hematology Clinical Pharmacist Specialist
Clinical Team Leader Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan – Michigan Medicine
Ann Arbor, Michigan
Fa...
2022-12-1949 min
Pharmacy Podcast NetworkAdvances in the Treatment of Immune Thrombocytopenia: Strategies for Optimizing Clinical and Patient Outcomes | PTCE Pharmacy ConnectEducational Objectives
Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP)
Recall the efficacy and safety of emerging agents for the treatment of ITP
Moderator:
Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
Clinical Team Leader Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan – Michigan Medicine
Ann Arbor, Michigan
Faculty:
Lisa Charneski, PharmD, BCPS
Assistant Dean for Academic Affairs
Philadelphia College of Pharmacy
As...
2022-12-1949 minWolverHeme Happy HourEpisode 9: ASH Recap Part 1 - Dauno-Double TroubleIn this episode, Anthony and Bernie begin to recap some interesting studies presented at ASH, starting with a discussion the results of the "Dauno-Double" Trial. Should it change practice?
Dauno-Double Trial: https://ash.confex.com/ash/2022/webprogram/Paper157126.html
Dr. Todd Lee breaking down the non-inferiority numbers: https://twitter.com/DrToddLee/status/1600662377250586627?s=20&t=RdIhJJpMG-G_oPUSH2u2mw
2022-12-1440 minWolverHeme Happy HourEpisode 8: Pulling the Goalie on FLT3 Inhibitor Use in AML - A Discussion with Dr. Dale BixbyIn this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and prognostic implications of FLT3+ AML, pitfalls and controversies of variant allele frequency and allelic ratio testing, and the data that informs the use of FLT3 inhibitors in AML. Watch out for some possibly heretical views!
REFERENCES
Schlenk and Dohner (Impact of AML prognostic markers)l: https://pubmed.ncbi.nlm.nih.gov/19468271/
RATIFY Trial...
2022-11-231h 22WolverHeme Happy HourEpisode (3+)7: Straight Outta Roswell - OG AML DataFinally back from a much needed vacation, in this episode, Anthony and Bernie discuss some of the "OG" data and pharmacology behind key AML therapies.
2022-10-0747 minWolverHeme Happy HourEpisode 6: Dr. StrangeDrug or: How I Learned to Stop Worrying and Love the AsparaginaseIn this episode, Bernie and Anthony do an in-depth dive into the pharmacology, toxicity management, and clinical conundrums with asparaginase therapy, including how and when to monitor asparaginase activity levels (per Papa Heme request!). For those who don't know (and maybe aren't as nerdy as we are), the title is a reference to the 1964 film Dr. Strangelove!
2022-07-211h 15
WolverHeme Happy HourEpisode 5: IDH Inhibitors in AML: not so AGILEIn this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosidenib in combination with azacitidine in newly diagnosed IDH1+ AML, based on the results of the AGILE study: https://www.nejm.org/doi/full/10.1056/NEJMoa2117344
2022-06-041h 24WolverHeme Happy HourEpisode 4: All Aboard the Oncology StewardSHIPIn this episode, Bernie Marini and Anthony Perissinotti are joined by two special guest hematology experts - Lydia Benitez, PharmD, BCOP, and Madeleine Ochs, PharmD, BCOP. Maddy and Lydia help us dive into the topic of Oncology Stewardship, including how we can incorporate Oncology Stewardship into practice to improve outcomes for patients.
Learn more about Oncology Stewardship in AML patients in our hot off the press paper in Annals of Hematology, written by Maddy (first author), Lydia (senior author), and the rest of our leukemia team:
https://link.springer.com/article/10.1007/s00277-022-04872-1
2022-05-2755 minWolverHeme Happy HourEpisode 3.2: Ranting About Rituximab in Acute Lymphoblastic LeukemiaIn part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (Marks, et al. Lancet Haematol, 2022): https://pubmed.ncbi.nlm.nih.gov/35358441/. We also discuss the previously published GRAALL study that evaluated rituximab in ALL (Maury, et al. NEJM, 2016, https://pubmed.ncbi.nlm.nih.gov/27626518/), and what we can conclude from the literature to date. The data surprises us, and makes us question our own practices!
2022-04-2350 minWolverHeme Happy HourEpisode 3.1: History of Acute Lymphoblastic Leukemia Treatment and Building the BFM BackboneIn part one of a two-part episode, Bernie Marini and Anthony Perissinotti take a journey through the history of acute lymphoblastic leukemia treatment throughout the decades and explain how we got to our current standard of care treatment of ALL patients. In part 2 we tackle the UKALL14 study evaluating the addition of rituximab to acute lymphoblastic leukemia therapy.
Some important historical articles that we reference:
Nitrogen mustard therapy: https://pubmed.ncbi.nlm.nih.gov/20997191/
Methotrexate/Aminopterin: https://www.nejm.org/doi/full/10.1056/nejm194806032382301
Vincristine: https://pubmed.ncbi.nlm.nih.gov/13627916/ and https://pubmed.ncbi.nlm.nih...
2022-04-2346 minWolverHeme Happy HourEpisode 2: We Don't Talk About RylazeBernie Marini and Anthony Perissinotti discuss asparaginase, the data (or lack thereof) behind the FDA approval of Rylaze (Erwinia asparaginase), and concerning trends regarding switches between asparaginase products in clinical practice!
2022-03-1844 minWolverHeme Happy HourEpisode 1: Surrogate Endpoints in AMLBernie Marini and Anthony Perissinotti discuss the following paper on whether or not event-free survival (EFS) is an appropriate surrogate endpoint for overall survival (OS) in AML:
Norsworthy KJ, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. J Clin Oncol. 2022 Mar 10;40(8):847-854. PMID: 34890212.
2022-03-1125 min
PTCE Pharmacy Connect | Pharmacy TimesImplementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support | PTCE Pharmacy ConnectImplementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support
Educational Objectives:
At the completion of this activity, participants will be able to:
Define the pharmacist’s role in implementing digital and telemedicine technologies within the health system to improve adherence and provide remote patient monitoring and management.
Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan
He has no relevant financial relationships with commercial interests to disclose.
PTCE is...
2021-05-2541 min
PTCE Pharmacy Connect | Pharmacy TimesImplementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support | PTCE Pharmacy ConnectImplementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support
Educational Objectives:
At the completion of this activity, participants will be able to:
Define the pharmacist’s role in implementing digital and telemedicine technologies within the health system to improve adherence and provide remote patient monitoring and management.
Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan
He has no relevant financial relationships with commercial interests to disclose.
PTCE is...
2021-05-2541 min
PTCE Pharmacy Connect | Pharmacy TimesOptimizing Safety & Efficacy of BTK Inhibitors | PTCE Pharmacy ConnectFoundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects
Educational Objectives:
At the completion of this activity, participants will be able to:
Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data
Recognize pharmacists’ responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types
Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Med...
2021-05-2546 min
PTCE Pharmacy Connect | Pharmacy TimesOptimizing Safety & Efficacy of BTK Inhibitors | PTCE Pharmacy ConnectFoundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects
Educational Objectives:
At the completion of this activity, participants will be able to:
Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data
Recognize pharmacists’ responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types
Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Med...
2021-05-2546 min